Zicam Maker Matrixx' Sales Plummet While Legal Costs Climb
This article was originally published in The Tan Sheet
Executive Summary
Zicam manufacturer Matrixx Initiatives' sales dropped more than 50 percent in its most recent quarter as its legal costs continue to grow
You may also be interested in...
Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.
Reformulated Zicam Nasal Swabs Return Matrixx To Top Sales Category
Matrixx Initiatives re-launches Zicam Cold Remedy Nasal Swabs with “plant-based ingredients” replacing the original product’s zinc gluconate. Consumer trust in the Zicam brand prompted the reformulation and re-launch, says CEO M’lou Walker.
Reformulated Zicam Nasal Swabs Return Matrixx To Top Sales Category
Matrixx Initiatives re-launches Zicam Cold Remedy Nasal Swabs with “plant-based ingredients” replacing the original product’s zinc gluconate. Consumer trust in the Zicam brand prompted the reformulation and re-launch, says CEO M’lou Walker.